Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.

Published in: Journal of gynecologic oncology (2019)

Apatinib can improve the disease control rate of recurrent and metastatic cervical cancer when chemotherapy has failed, and the treatment is well tolerated. This represents that apatinib may be a new treatment option for metastatic cervical cancer patients.

Keyphrases

squamous cell carcinoma
small cell lung cancer
locally advanced
clinical trial
randomized controlled trial
radiation therapy
smoking cessation